Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296229 | 0.95 | MAPT (0.59) | MAPTRAB9AKDM4EGAANPC1 | |
| SCHEMBL15000306 | 0.89 | RAB9A (0.60) | MAPTRAB9AKDM4EGAANPC1 | |
| SCHEMBL296768 | 0.87 | KDM4E (0.48) | MAPTRAB9AKDM4ENPC1ADRB2 | |
| SCHEMBL298442 | 0.87 | MAPT (0.36) | MAPTRAB9AKDM4EGAAJAK3 | |
| SCHEMBL297472 | 0.83 | KDM4E (0.40) | MAPTRAB9AKDM4EGAANPC1 | |
| SCHEMBL286507 | 0.81 | KDM4E (0.39) | MAPTRAB9AKDM4EGAANPC1 | |
| SCHEMBL286674 | 0.81 | KDM4E (0.51) | MAPTRAB9AKDM4EGAANPC1 | |
| SCHEMBL296746 | 0.80 | RAB9A (0.43) | MAPTRAB9AKDM4ENPC1LMNA | |
| SCHEMBL286384 | 0.79 | SYK (0.44) | RAB9AKDM4EGAANPC1TP53 | |
| SCHEMBL296262 | 0.78 | KDM4E (0.46) | MAPTRAB9AKDM4EGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020716-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-11-12 | — | — | US | disclosed |
| EP-2617420-B1 | Phenoxymethyl heterocyclic compounds | FORUM PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-8946222-B2 | Phenoxymethyl heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2617420-A1 | Phenoxymethyl heterocyclic compounds | Envivo Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHAMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2427454-B1 | Phenoxymethyl heterocyclic compounds | ENVIVO PHARMACEUTICALS INC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8343973-B2 | Phenoxymethyl heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2427454-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | ADRB2 1090/4885MAPT 1299/4885RAB9A 1008/4885 |
| US-20130143888-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | ADRB2 1090/4885MAPT 1299/4885RAB9A 1008/4885 |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | ADRB2 1090/4885MAPT 1299/4885RAB9A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.